Cargando…

Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer

PURPOSE: This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments. METHODS: Women with non-metastatic breast cancer were recruited before primary therapy. In four weeks distr...

Descripción completa

Detalles Bibliográficos
Autores principales: Helbrich, H., Braun, M., Hanusch, C., Mueller, G., Falk, H., Flondor, R., Harbeck, N., Hermelink, K., Wuerstlein, R., Keim, S., Neufeld, F., Steins-Loeber, S., Haertl, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260526/
https://www.ncbi.nlm.nih.gov/pubmed/33788134
http://dx.doi.org/10.1007/s10549-021-06195-7
_version_ 1783718825477275648
author Helbrich, H.
Braun, M.
Hanusch, C.
Mueller, G.
Falk, H.
Flondor, R.
Harbeck, N.
Hermelink, K.
Wuerstlein, R.
Keim, S.
Neufeld, F.
Steins-Loeber, S.
Haertl, K.
author_facet Helbrich, H.
Braun, M.
Hanusch, C.
Mueller, G.
Falk, H.
Flondor, R.
Harbeck, N.
Hermelink, K.
Wuerstlein, R.
Keim, S.
Neufeld, F.
Steins-Loeber, S.
Haertl, K.
author_sort Helbrich, H.
collection PubMed
description PURPOSE: This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments. METHODS: Women with non-metastatic breast cancer were recruited before primary therapy. In four weeks distributed over six months after treatment start, patients reported time spent on work, transport, chores and sports via diary and wore Garmin(®) vivofit 3 accelerometers to assess steps taken. Associations between these measures and agreement regarding guideline adherence were tested with Spearman’s Correlation Coefficient and Weighted Kappa statistic. Effects of time and treatment were evaluated using mixed analyses of variance. RESULTS: Ninety-nine participants (median age = 50) were treated with adjuvant (N = 23), neoadjuvant (N = 21) or without chemotherapy (N = 55). Coherence between self-report and device data was strong (r = 0.566). Agreement about reaching recommendations was only “fair” (kappa coefficient = 0.321 and 0.249, resp.). Neither treatment or week nor their interaction had effects on step counts (all p > 0.05). Self-reported activity time was lower for patients with chemotherapy than for those without (adjuvant: ∆ = 69min, p = 0.006, neoadjuvant: ∆ = 45min, p = 0.038) and lower in week 18 than in week 3 (∆ = 43min, p = 0.010). CONCLUSION: Results show that consumer-grade activity monitors and self-reports correlate but show different perspectives on physical activity in breast cancer patients. In general, patients perceive some decline regardless of primary treatment regimen. Those affected should be offered assistance to gain the benefits of activity. Accelerometers may help professionals to identify these individuals and patients to verify appraisal of their activity levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06195-7.
format Online
Article
Text
id pubmed-8260526
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82605262021-07-20 Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer Helbrich, H. Braun, M. Hanusch, C. Mueller, G. Falk, H. Flondor, R. Harbeck, N. Hermelink, K. Wuerstlein, R. Keim, S. Neufeld, F. Steins-Loeber, S. Haertl, K. Breast Cancer Res Treat Clinical Trial PURPOSE: This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments. METHODS: Women with non-metastatic breast cancer were recruited before primary therapy. In four weeks distributed over six months after treatment start, patients reported time spent on work, transport, chores and sports via diary and wore Garmin(®) vivofit 3 accelerometers to assess steps taken. Associations between these measures and agreement regarding guideline adherence were tested with Spearman’s Correlation Coefficient and Weighted Kappa statistic. Effects of time and treatment were evaluated using mixed analyses of variance. RESULTS: Ninety-nine participants (median age = 50) were treated with adjuvant (N = 23), neoadjuvant (N = 21) or without chemotherapy (N = 55). Coherence between self-report and device data was strong (r = 0.566). Agreement about reaching recommendations was only “fair” (kappa coefficient = 0.321 and 0.249, resp.). Neither treatment or week nor their interaction had effects on step counts (all p > 0.05). Self-reported activity time was lower for patients with chemotherapy than for those without (adjuvant: ∆ = 69min, p = 0.006, neoadjuvant: ∆ = 45min, p = 0.038) and lower in week 18 than in week 3 (∆ = 43min, p = 0.010). CONCLUSION: Results show that consumer-grade activity monitors and self-reports correlate but show different perspectives on physical activity in breast cancer patients. In general, patients perceive some decline regardless of primary treatment regimen. Those affected should be offered assistance to gain the benefits of activity. Accelerometers may help professionals to identify these individuals and patients to verify appraisal of their activity levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06195-7. Springer US 2021-03-31 2021 /pmc/articles/PMC8260526/ /pubmed/33788134 http://dx.doi.org/10.1007/s10549-021-06195-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Trial
Helbrich, H.
Braun, M.
Hanusch, C.
Mueller, G.
Falk, H.
Flondor, R.
Harbeck, N.
Hermelink, K.
Wuerstlein, R.
Keim, S.
Neufeld, F.
Steins-Loeber, S.
Haertl, K.
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title_full Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title_fullStr Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title_full_unstemmed Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title_short Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
title_sort congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260526/
https://www.ncbi.nlm.nih.gov/pubmed/33788134
http://dx.doi.org/10.1007/s10549-021-06195-7
work_keys_str_mv AT helbrichh congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT braunm congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT hanuschc congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT muellerg congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT falkh congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT flondorr congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT harbeckn congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT hermelinkk congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT wuerstleinr congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT keims congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT neufeldf congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT steinsloebers congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer
AT haertlk congruenceandtrajectoriesofdevicemeasuredandselfreportedphysicalactivityduringtherapyforearlybreastcancer